齐拉西酮与阿立哌唑对血清催乳素及体重的影响

The effects of Ziprasidone and Aripiprazole on serum prolactin level and body weight of schizophrenia patients

目的 探讨精神分裂症患者应用齐拉西酮与阿立哌唑治疗前后对血清催乳素（PRL）及体重的影响.方法 对60例未曾治疗或停药3个月的精神分裂症患者随机给予齐拉西酮与阿立哌唑规范治疗,于治疗前及治疗第8周末用化学发光法测查患者PRL水平并监测体重,进行对比分析.结果 服用齐拉西酮、阿立哌唑患者治疗前后血清催乳素及体重无明显变化（P＞0.05）;同组间比较,治疗前后血清催乳素及体重亦无显著差异（P＞0.05）,性别对血清催乳素无明显影响（P＞0.05）.结论 齐拉西酮与阿立哌唑对患者血清催乳素及体重无升高作用,是较安全的新型抗精神病药物.

Objective To evaluate the effects of Ziprasidone and Aripipraz-- ole on serum prolac tin level and body weight of schizophrenia patients. Methods Sixty schizophrenia patients who had not been treated with any psychotropics were included and treated with Ziprasidone and Aripiprazole. Serum prolactin level and body weight were tested and measured before and eight weeks after treatment. Results The serum prolactin level and body weight did not change significantly before and after Ziprasidone and Aripiprazole treatment （P 〉 0.05）. The change of serum prolaetin level after treatment with ziprasidone and Aripiprazole was not associated with sexes （P 〉 0.05）. Conclusions Ziprasidone and Aripiprazole has no effect on serum prolactin and body weight. Ziprasidone and Aripiprazol are safe drugs in the treat- ment of schizophrenia.